GlucoTrack secures $4M funding from its leading shareholder for CBGM trial

Glucotrack announced that it has secured $4M in funding from its leading shareholder to support the upcoming First in Human clinical trial. “This year, we have made significant progress in the development of our groundbreaking Continuous Blood Glucose Monitor CBGM technology. This funding, by long-standing investor John Ballantyne, provides increased financial flexibility for the Company as we embark on human clinical trials for this less burdensome approach to glucose monitoring,” said CEO Paul V. Goode, PhD. “Since my initial investment, the Company has undergone a significant evolution in its technology and focus. This has accelerated development of the innovative CBGM which has the potential to be disruptive in a large and growing diabetes market. I remain confident that the Company and its leadership team are well positioned to deliver strong clinical value to the diabetes community and meaningful value to the shareholder community,” said John Ballantyne.